One Million Americans with Blood Cancer in Jeopardy of Losing Access to …Sacramento BeeSome of these include therapies for patients with chronic myelogenous leukemia such as imatinib, dastatinib, bosutinib, nilotinib and ponatinib; lenalidomide and t…
Clinical Oncology NewsClinical Hematologic Review: Highlights from ASH and NEJM, JCO and BloodClinical Oncology NewsInvestigators from MD Anderson Cancer Center presented encouraging Phase II data showing ibrutinib (PCI-32765, Janssen) in combination w…
One Million Americans with Blood Cancer in Jeopardy of Losing Access to …PR Newswire (press release)Some of these include therapies for patients with chronic myelogenous leukemia such as imatinib, dastatinib, bosutinib, nilotinib and ponatinib; lenal…
 FRANCE 24 |
Biogen Idec to Acquire Full Rights and Control of TYSABRI from Elan for …
Businessweek … including uncertainty inherent in regulatory review of the transaction, our dependence on our three principal products, AVONEX™ (interferon beta-1a), TYSABRI and RITUXAN™ (rituximab), the importance of TYSABRI’s sales growth, uncertainty of … Biogen Idec to Acquire Full Rights and Control of TYSABRI(R) from Elan for …MarketWatch (press release) |
|
Biogen Idec to Acquire Full Rights and Control of TYSABRI® from Elan for …
The Herald | HeraldOnline.com … (interferon beta-1a), TYSABRI and RITUXAN® (rituximab), the importance of TYSABRI’s sales growth, uncertainty of success in commercializing and developing other products, product competition, the occurrence of adverse safety events with our … |
New Zealand takes significant step towards national hospital medicines listThe Pharma LetterOne of the changes has been the addition of rituximab (MabThera, from Roche) to the rheumatology list. Rituximab, a targeted biologic medicine, had already been…
High-dose Vorinostat effective at treating relapsed lymphomasHealthCanal.comPreclinical studies at Fred Hutch and other research centers have found Vorinostat to be effective when used along with the standard chemotherapy combo, which is known by the a…
Cells Predict Onset of Graft-Versus-Host Disease in Men Receiving Bone …Science Daily (press release)Miklos and his associates have shown in other studies that an injectable drug called rituximab (itself an antibody) that attacks B cells while sparin…
|
No hay riesgos por Rituximab
Comunicado-Prensa.com (Comunicado de prensa) Hasta la fecha no hay ningún reporte confirmado del riesgo de efectos adversos graves de Rituximab ni muertes asociadas al tratamiento con este medicamento. Así lo confirma un comunicado del Laboratorio Roche, que comercializa Rituximab en … |
PHARMAC takes significant step towards national hospital medicines listNew Zealand Doctor OnlineOne of the changes has been the addition of rituximab (Mabthera) to the rheumatology list. Rituximab, a targeted biologic medicine, had already been availab…